SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
February 03, 2023 15:32 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Feb. 03, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic...
Chronic Pain Market is Estimated to Record a CAGR of 6.9% During the Forecast Period 2023 – 2033 | Future Market Insights, Inc.
December 31, 2022 05:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Dec. 31, 2022 (GLOBE NEWSWIRE) -- The chronic pain market is anticipated to grow from US$ 73.14 Bn in 2023 to US$ 142.53 Bn by 2033, rising at a CAGR of 6.9% during the forecast period....
IGC Announces Updated Life Sciences Presentation
December 20, 2022 08:30 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with...
Le lieutenant-général (ret) J.O. Michel Maisonneuve dirigera la campagne de financement à l’appui de la recherche et des traitements pour les vétérans vivant avec la douleur chronique
November 10, 2022 07:00 ET
|
Centre d’excellence sur la douleur chronique pour les vétérans canadiens
HAMILTON, Ontario, 10 nov. 2022 (GLOBE NEWSWIRE) -- Le Centre d’excellence sur la douleur chronique pour les vétérans canadiens (CESLDC) est heureux d’annoncer la nomination du lieutenant-général...
Lieutenant-General (retired) J.O. Michel Maisonneuve to lead fundraising efforts supporting research and treatment for Veterans experiencing chronic pain
November 10, 2022 07:00 ET
|
Chronic Pain Centre of Excellence for Canadian Veterans
HAMILTON, Ontario, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Chronic Pain Centre of Excellence for Canadian Veterans (CPCoE) is excited to announce it has appointed Lieutenant-General (retired) J.O....
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
Canadian Military Veterans Complete Hike to Bring Awareness to Chronic Pain
August 30, 2022 07:32 ET
|
Chronic Pain Centre of Excellence for Canadian Veterans
HAMILTON, Ontario, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seven military Veterans living with chronic pain from across Canada completed the first-ever Military Veterans Alpine Challenge (Alpine...
Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs
August 02, 2022 16:23 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs. In this role, he will provide...
SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
July 14, 2022 10:54 ET
|
SPR Therapeutics, Inc.
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of...
Global Neuromodulation Market to Reach $4.3 Bn Globally, by 2030, at 6.2% CAGR: Says AMR
June 15, 2022 07:47 ET
|
Allied Market Research
Portland, OR, June 15, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Neuromodulation Market was estimated at $2.48 billion in 2020, and is...